Dr. Wolff Group Working with Kinaxis and mSE Solutions to Bring Supply Chain Clarity to Personal Care Product Portfolio
Kinaxis® Inc. (TSX: KXS), a global leader in end-to-end supply chain orchestration, today announced that Dr. Wolff Group, a family-owned German manufacturer of cosmetic and pharmaceutical products, is working with Kinaxis, along with mSE Solutions, an expert supply chain optimization consultancy, to help drive faster and more accurate decision-making in supply chain planning and thus ensure a better balance between market and supply chain dynamics.
A growing company that exports its popular brands including Alpecin, Alcina, and Plantur among others, to more than 60 countries worldwide, Dr. Wolff faced challenges in managing its complex and diverse product portfolio that includes everything from hair care and styling products, to decorative cosmetics, dental care, and vaginal and dermatologic pharmaceuticals. In order to be able to react even more flexibly, quickly and efficiently to customer requirements, the company turned to mSE Solutions and Kinaxis to strengthen its supply chain processes.
By bringing together the strengths of their expert teams, Kinaxis and mSE Solutions will help Dr. Wolff Group in the end-to-end orchestration of the global supply chain by implementing Kinaxis' AI-powered platform.
“The diversity of our products and expansion into new markets make our supply chain particularly complex and challenging,” said Dr. Andreas Brinkhoff, Managing Director at Dr. Wolff Group. “mSE Solutions helped to identify the areas of our business that would benefit the most from supply chain orchestration technologies and by partnering with Kinaxis, we are developing a comprehensive view of our supply chain performance and risks across our entire end-to-end network. We are now prepared to respond to any disruptions.”
“Marked by hyper-competition, high volumes, and a frenetic pace, the consumer-packaged goods industry operates with a constant need for supply chain agility and efficiency,” said Martin Bilstein, regional vice president, DACH region at Kinaxis. “We’re thrilled to be part of the supply chain evolution that Dr. Wolff Group is undertaking and looking forward to supporting their success.”
To learn more about Kinaxis and its supply chain management solutions, please visit Kinaxis.com.
About Kinaxis
Kinaxis is a global leader in modern supply chain orchestration. We serve supply chains and the people who manage them in service of humanity. Our software is trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. We combine our patented concurrency technique with a human-centered approach to AI to empower businesses of all sizes to manage their end-to-end supply chain network, from multi-year strategic planning through down-to-the-second execution and last-mile delivery. For more news and information, please visit kinaxis.com or follow us on LinkedIn.
About mSE Solutions
mSE Solutions is your tech-savvy Supply Chain consultancy, dedicated to asking the right questions, providing expert guidance, and delivering top-notch services for your successful Kinaxis implementation. Our goal is to ensure that your transformation journey is quick, effective, and embraced by your users. With a global reach, our services extend to post-go-live support and system maintenance, offering comprehensive assistance wherever your business operates. For ambitious small or medium-sized enterprises – the hidden champions of their industries – mSE Solutions is the ideal, hands-on partner for Kinaxis RapidResponse implementations. Please visit mSE-solutions.com.
About Dr. Wolff-Group
Now led by the fourth generation of its founding family and with brands including Alpecin and Linola as well as Plantur, Vagisan Karex and Bioniq®, the Germany-based Dr. Wolff-Group with around 900 employees continues its global growth. Since its founding 1905, the company has maintained a strong emphasis on research and scientifically demonstrable benefits of its products for solving problems such as hair loss or skin disorders. With their own developments, the company was able to achieve a turnover of 390.6 million Euro (2023). Dr. Wolff is active in 67 countries. More information can be found at www.drwolffgroup.com/en/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240910214030/en/
Contacts
Media Relations
Jaime Cook | Kinaxis
jcook@kinaxis.com
+1 289-552-4640
Investor Relations
Rick Wadsworth | Kinaxis
rwadsworth@kinaxis.com
613-907-7613
mSE Solutions
Kerstin Olasik
kerstin.olasik@mse-solutions.com
Dr. Wolff Group
Nina Lauterbach
Nina.lauterbach@drwolffgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 22:46:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 22:35:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 21:32:00 EET | Press release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
Aarhus University: New Global Study Sheds Light on the Learning Crisis: Three Years After COVID-1920.12.2024 14:00:00 EET | Press release
TIMSS 2023 has revealed an alarming global learning crisis exacerbated by the COVID-19 pandemic. Compared to the long term trend in progress in mathematics and science achievement has not only stalled but reversed when taking school closures into account, with the most vulnerable students facing the steepest losses. Key Findings Global Achievement Decline: A 0.11 standard deviation drop in student performance reflects the pandemic's lasting impact. Disproportionate Impact: Low performers, girls, and language minorities faced losses up to twice the average (0.22 standard deviations), deepening existing inequities. Regional Variations: Countries with prolonged school closures and limited remote learning resources experienced the steepest declines. Why This Matters School closures disrupted the education of over one billion children worldwide, with disadvantaged students suffering the most. “The widening gender gap in STEM fields is particularly troubling,” said Christian Kjeldsen, incomi
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 14:00:00 EET | Press release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom